Protecting communities in pharmacogenetic and pharmacogenomic research

被引:24
作者
Weijer, C [1 ]
Miller, PB [1 ]
机构
[1] Dalhousie Univ, Dept Bioeth, Halifax, NS B3H 4H7, Canada
关键词
pharmacogenetics; genetics databases; bioethics; human experimentation; culture; research standards;
D O I
10.1038/sj.tpj.6500219
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The existing EELS literature has usefully identified the scope of ethical issues posed by pharmacogenetic and pharmacogenomic research. The time has come for in-depth examination of particular ethical issues. The involvement of racial and ethnic communities in pharmacogenetic and pharmacogenomic research is contentious precisely because it touches upon the science and politics of studying racial and ethnic difference. To date, the ethics literature has not seriously taken account of the fact that such research impinges upon the interests of communities, and that taking such interests seriously requires that we both protect and empower communities in research. We propose a framework that rests upon the recognition that communities are heterogeneous human associations and differing policies are appropriate for differing communities. Community consent and consultation and community consultation alone are neither appropriate nor required for all pharmacogenetic and pharmacogenomic research. Rather, application of these policy protections must take into account particulars of both planned research and the communities involved.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 41 条
[1]   Pharmacogenomics: Ethical concerns for research and pharmacy practice [J].
Alcalde, MG ;
Rothstein, MA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (22) :2239-2240
[2]   MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].
Ameyaw, MM ;
Regateiro, F ;
Li, T ;
Liu, XH ;
Tariq, M ;
Mobarek, A ;
Thornton, N ;
Folayan, GO ;
Githang'a, J ;
Indalo, A ;
Ofori-Adjei, D ;
Price-Evans, DA ;
McLeod, HL .
PHARMACOGENETICS, 2001, 11 (03) :217-221
[3]  
[Anonymous], COD COND RES INV HUM
[4]  
[Anonymous], PHARMACOGENETICS ETH
[5]   Informed consent for population-based research involving genetics [J].
Beskow, LM ;
Burke, W ;
Merz, JF ;
Barr, PA ;
Terry, S ;
Penchaszadeh, VB ;
Gostin, LO ;
Gwinn, M ;
Khoury, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18) :2315-2321
[6]   Pharmacogenetics: Ethical issues and policy options [J].
Buchanan, A ;
Califano, A ;
Kahn, J ;
McPherson, E ;
Robertson, J ;
Brody, B .
KENNEDY INSTITUTE OF ETHICS JOURNAL, 2002, 12 (01) :1-15
[7]   The importance of race and ethnic background in biomedical research and clinical practice [J].
Burchard, EG ;
Ziv, E ;
Coyle, N ;
Gomez, SL ;
Tang, H ;
Karter, AJ ;
Mountain, JL ;
Pérez-Stable, EJ ;
Sheppard, D ;
Risch, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1170-1175
[8]   Sulfation pharmacogenetics:: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects [J].
Carlini, EJ ;
Raftogianis, RB ;
Wood, TC ;
Jin, F ;
Zheng, W ;
Rebbeck, TR ;
Weinshilboum, RM .
PHARMACOGENETICS, 2001, 11 (01) :57-68
[9]   Race, ethnicity, and genomics: Social classifications as proxies of biological heterogeneity [J].
Foster, MW ;
Sharp, RR .
GENOME RESEARCH, 2002, 12 (06) :844-850
[10]   Pharmacogenetics, race, and ethnicity: Social identities and individualized medical care [J].
Foster, MW ;
Sharp, RR ;
Mulvihill, JJ .
THERAPEUTIC DRUG MONITORING, 2001, 23 (03) :232-238